Valeant Weighs New Viramidine Dosing After Phase III Stumble
This article was originally published in The Pink Sheet Daily
Prediction of a 2007 launch is unaltered by failure of first pivotal hepatitis C trial to meet one of two co-primary endpoints.
You may also be interested in...
Company will reconsider dosing for its hepatitis C candidate.
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.